November 22 | 2019
2cureX publishes interim report for the third quarter of 2019
Read more
November 6 | 2019
2cureX continues its efforts to ensure a strong IP protection for its IndiTreat test in the United States
Read more
October 15 | 2019
2cureX continues its IP expansion by securing a patent on Its IndiTreat test in Hong Kong
Read more
October 8 | 2019
2cureX has made an agreement with one of the largest private cancer hospitals in the Nordic countries
Read more
September 25 | 2019
2cureX Newsletter September 2019
Read more
August 23 | 2019
2cureX publishes half-year report for the first half of 2019
Read more
July 23 | 2019
2cureX announces that patients are successfully being enrolled in the IndiTreat® pancreatic cancer trial
Read more
June 27 | 2019
Last day of trading in BTA 1 in 2cureX AB
Read more
June 25 | 2019
Change of Certified Adviser to Svensk Kapitalmarknadsgranskning AB
Read more
June 20 | 2019
2cureX appoints Dr. Med. Henrik Harling as Chief Medical Officer
Read more
May 28 | 2019
Communique from the Annual General Meeting in 2cureX AB (publ)
Read more
May 28 | 2019
Significantly oversubscribed rights issue in 2cureX AB
Read more
May 10 | 2019
2cureX invites to an investor meeting in Stockholm on May 15th, 2019
Read more
May 9 | 2019
Today, the subscription period starts in 2cureX’s rights issue
Read more
May 8 | 2019
2cureX publishes memorandum ahead of the rights issue
Read more
May 8 | 2019
2cureX publishes interim report for the first quarter of 2019
Read more
May 7 | 2019
2cureX publishes the annual report for the fiscal year 2018
Read more